4-[4-(trifluoromethyl)phenyl]phthalazin-1(2H)-one | 137382-42-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4-[4-(trifluoromethyl)phenyl]phthalazin-1(2H)-one
• 英文别名: 4-[4-(trifluoromethyl)phenyl]-2H-phthalazin-1-one
• CAS: 137382-42-4
• 化学式: C₁₅H₉F₃N₂O
• 分子量: 290.244
• InChiKey: ZJUNDHXEJDABNT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  41.5
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-[4-(trifluoromethyl)phenyl]phthalazin-1(2H)-one 在 sodium hydride 、 sodium carbonate 、 sodium iodide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.5h， 生成 4-[4-(trifluoromethyl)phenyl]-2-[3-[4-[3-(acetylamino)phenyl]piperidin-1-yl]propyl]phthalazin-1(2H)-one
  参考文献：
  名称：

  4-Arylphthalazin-1(2H)-one derivatives as potent antagonists of the melanin concentrating hormone receptor 1 (MCH-R1)

  摘要：

  A novel series of 4-arylphthalazin-1(2H)-one linked to arylpiperidines were synthesized and evaluated as MCH-R1 antagonists. The results of an extensive SAR study probing the effects of substituents on the 4-arylphthalazin-1(2H)-one C-4 aryl group led to the identification of the 4-(3,4-difluorophenyl) derivative as a highly potent MCH-R1 inhibitor with an IC50 = 1 nM. However, further investigations showed that this substance has unacceptable pharmacokinetic properties including a high clearance and volume of distribution. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.10.111
• 作为产物：
  描述：

  4-三氟甲基苯基溴化镁 在 一水合肼 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 5.5h， 生成 4-[4-(trifluoromethyl)phenyl]phthalazin-1(2H)-one
  参考文献：
  名称：

  Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. 1. 2-[2-(1-Imidazolyl)alkyl]-1(2H)-phthalazinones

  摘要：

  A number of 4-substituted 2-[omega-(1-imidazolyl)allryl]-1(2H)-phthalazinones were synthesized in order to develop agents possessing both thromboxane Az synthetase inhibitory and bronchodilatory activities. The pharmacological evaluation of these compounds disclosed that they have both activities to various extents. Both activities were slightly dependent on the length of the 2-substituents and largely affected by the nature of the 4-substituents. Compounds bearing phenyl and thienyl groups exhibited relatively high and well-rounded activities. Among these compounds, 12j and 15f were found to be the most effective agents having well-rounded activities in vitro and in vivo. Introduction of a carboxyl group reduced both activities contrary to our expectation. 4-(3-Pyridyl)phthalazinone 18b was of particular interest because of unexpectedly high in vivo activities in spite of an absence of significant in vitro activities.

  DOI：

  10.1021/jm00077a008

文献信息

• POTASSIUM CHANNEL MODULATORS
  申请人：Brown Brian S.

  公开号：US20110124642A1

  公开（公告）日：2011-05-26

  Disclosed herein are KCNQ potassium channels modulators of formula (I) wherein ring Z 1 , R 1 , p, R 3 , and R 4 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.

  本文披露了具有以下结构的KCNQ钾通道调节剂（I）： 其中环Z 1 ，R 1 ，p，R 3 和R 4 如规范中所定义。还描述了包含这些化合物的组合物；以及使用这些化合物和组合物治疗疾病和疾病的方法。
• US8629143B2
  申请人：——

  公开号：US8629143B2

  公开（公告）日：2014-01-14
• [EN] POTASSIUM CHANNEL MODULATORS<br/>[FR] MODULATEURS DES CANAUX POTASSIQUES
  申请人：ABBOTT LAB

  公开号：WO2011066168A1

  公开（公告）日：2011-06-03

  Disclosed herein are KCNQ potassium channels modulators of formula (I) wherein ring Z1, R1, p, R3, and R4 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.
• [EN] BICYCLIC HETEROAROMATIC COMPOUNDS FOR TREATING CANCER<br/>[FR] COMPOSÉS HÉTÉROAROMATIQUES BICYCLIQUES POUR LE TRAITEMENT DU CANCER
  申请人：[en]ASTRAZENECA AB

  公开号：WO2023209086A1

  公开（公告）日：2023-11-02

  The specification relates to compounds of Formula (I): (I) and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of cancer.
• Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. 1. 2-[2-(1-Imidazolyl)alkyl]-1(2H)-phthalazinones
  作者：Masahisa Yamaguchi、Kenshi Kamei、Takaki Koga、Michitaka Akima、Toshio Kuroki、Nobuhiro Ohi

  DOI：10.1021/jm00077a008

  日期：1993.12

  A number of 4-substituted 2-[omega-(1-imidazolyl)allryl]-1(2H)-phthalazinones were synthesized in order to develop agents possessing both thromboxane Az synthetase inhibitory and bronchodilatory activities. The pharmacological evaluation of these compounds disclosed that they have both activities to various extents. Both activities were slightly dependent on the length of the 2-substituents and largely affected by the nature of the 4-substituents. Compounds bearing phenyl and thienyl groups exhibited relatively high and well-rounded activities. Among these compounds, 12j and 15f were found to be the most effective agents having well-rounded activities in vitro and in vivo. Introduction of a carboxyl group reduced both activities contrary to our expectation. 4-(3-Pyridyl)phthalazinone 18b was of particular interest because of unexpectedly high in vivo activities in spite of an absence of significant in vitro activities.